Objective: To examine the relationship between primary care medical home clinical practice systems corresponding to the domains of the Chronic Care Model and annual diabetes-related health care costs incurred by members of a health plan with type-2 diabetes and receiving care at one of 27 Minnesota-based medical groups.
H ealth care spending continues to increase well beyond the rate of other sectors of our economy. Patients with diabetes consume 250% more health care resources compared with peers without diabetes. 1 Unfortunately, there have not been commensurate improvements in quality, [2] [3] and there is ample evidence of variation in resource use and quality across physicians and medical groups. 4 The concept of a Patient-Centered Medical Home (PCMH), which originated with the American Academy of Pediatrics in 1967, is receiving increased attention as a potential means to improve care. [5] [6] Payers, purchasers, and policy makers see it as a vehicle for moderating costs and improving quality. [7] [8] [9] [10] High-functioning medical homes may facilitate patient-centeredness in primary care, resulting in improved patient satisfaction. 11 For example, adults reporting a usual source of care are 25% more likely to report positive clinician attributes, 12 and reduced racial and ethnic disparities have also been identified. 13 Clinical practice systems are recognized as an important component of the PCMH. National Committee for Quality Assurance's nationally endorsed tool, the Physician Practice Connections-Patient-Centered Medical Home standards (PPC-PCMH), measures the use of defined practice systems and is being used in many of the PCMH pilot programs. [14] [15] [16] [17] Prior research has indicated that the use of some of the same clinical practice systems posited as part of the medical home result in improved clinical care for patients with diabetes. 18 Although some reports of implementation of PCMH-like models of practice have reported cost reductions, [19] [20] [21] [22] studies linking the use of specific systems to resource use/cost are few and do not attempt to focus on disease-specific costs. 23 This study conducts a secondary data analysis of the relationship between clinical practice systems and annual diabetes costs. The research described in this paper explores the relationship between the research version of the PPC tool and costs of care for patients with diabetes. It focuses on 3 outcomes: (1) total cost of diabetes-related care; (2) outpatient medical costs of diabetes-related care; and (3) inpatient costs of diabetes-related care (eg, hospital stays and/or emergency department use). It hypothesizes that PCMH-related clinical systems are associated with reduced diabetes-related medical costs.
METHODS

Data Sources
Data came from the following sources. Practice system measures came from a medical director survey of Minnesotabased primary care medical groups. Patient demographics and diabetes-related costs came from health plan administrative databases. Clinical outcome data came from Minnesota Community Measurement (MNCM). The study was reviewed, approved in advance, and monitored by the HealthPartners (HP) Institutional Review Board.
Measure of PCMH Practice Systems: The PPC-RS
Based on the Chronic Care Model, 24 the Physician Practice Connections Readiness Survey (PPC-RS) is a 53question instrument measuring the presence of clinical practice systems. Three questions relate to Health Care Organization (HCO), 8 to Delivery System Redesign, 10 to Clinical Information Systems, 9 to Decision Support, and 23 to Self-Management Support (Table 1 ). Items are coded as working well (1 point), needing improvement (1/2 point), or absent (0 points). Domain scores are the proportion of items working well. Its association to quality has been shown. 18, [25] [26] A full description of the tool, it's scoring, and a crosswalk of the PPC-RS and PPC-PCMH are available on request.
HP Administrative Data
HP administrative databases contain information regarding medical diagnoses and care, pharmacy fills, utilization, demographics, and costs. All claims including pharmacy for dually eligible beneficiaries aged 65-75 years are processed by the health plan to track benefits, deductibles, and payer liability. The number of fills of outpatient pharmaceutical scripts was grouped into 4 categories: glucose lowering, hypertension control, cholesterol lowering, and other. Some patients (148) did not have full prescription data because of payer mix (ie, dual payer or pharmacy carve-out). These data were imputed using multiple regressions. [27] [28] [29] MNCM MNCM is a community collaborative that has reported medical group quality since 2002. 30 MNCM obtains the following data by yearly medical record review of a minimum sample of 60 diabetes patients per medical group: tobacco use, daily aspirin use, body mass index, congestive heart failure (CHF), cardiovascular disease (CVD), asthma, chronic obstructive pulmonary disease (COPD), and hypertension (HTN).
Study Population Medical Groups
In 2005, medical directors of 41 Minnesota-based primary care medical groups were surveyed using the PPC-RS. Two groups shared a common owner and integrated systems and were combined. The responses of 1 medical group were incomplete, and 12 others had no patients in the MCMN sample who were members of the health plan.
Subjects
Our unit of analysis included patients diagnosed with type-II diabetes. We identified health plan members with diabetes using the following validated definition that closely matches that used in physician-level Healthcare Effectiveness Data and Information Set diabetes-quality measures: (1) Z1 inpatient or Z2 outpatient International Classification of Diseases (ICD)-9 codes 250.xx without a type I subclassification, or (2) a filled prescription for a diabetesspecific medication other than a biguanide. Biguanide (metformin) use required at least one 250.xx code, because it is used for other conditions. Our identification algorithm excluded patients with codes for gestational diabetes. This diabetes identification method has an estimated sensitivity of 0.91 and a positive predictive value of 0.94. 31
Inclusion Criteria
The following were applied resulting in the identification of 8338 persons:
(i) diagnosed type-II diabetes;
(ii) enrolled in the health plan as of 1/1/2005; (iii) 12 months of continuous enrollment with a < 15-day interruption; 
Exclusion Criteria
The following exclusion criteria were applied: (i) no MNCM Chart Review (5301 exclusions); (ii) not attributed to one of the 27 primary care medical groups completing the PPC-RS (903 exclusions); (iii) a modified Charlson comorbidity score > 3 (126 exclusions).
Patients were attributed to medical groups on the basis of the primary care visits as determined by evaluation and management, E&M, codes. 32 A medical group was required to provide >50% of a patient's primary care for that patient to be attributed. Those with < 50% attributable to a single medical group were excluded. The average proportion of office visits attributable to a primary care medical group was 67.5%.
The modified Charlson comorbidity score excluded diabetes as a condition. Consistent with previous studies, 4, [33] [34] [35] persons with a Charlson score of > 3 were excluded for the following reasons: with a high likelihood of death within 1 year ( > 52%) and confounding disease burden, they represented a small, medically complex group with significantly higher average costs ($8536 average total diabetes-related costs), and they were concentrated in 5 medical groups making a cross-sectional analysis unreliable.
Study Outcomes
Claims data were organized using the Episode Symmetry (ESE) software. 36 For acute events, the ESE algorithm constructs episode treatment groups based on serially occurring Current Procedural Terminology (CPT) and ICD codes. For chronic diseases such as diabetes, the ESE algorithm groups all related E&M, ICD, and CPT codes (lipid panels, insulin, emergency department visits, hospitalizations, etc.) occurring within a predefined time-window of 12 months. Our time-window ranged from 1/1/2006 to 12/31/ 2006. Utilization more closely associated with other conditions or triggered by acute events is allocated to other episode treatment groups. A claim can be allocated to multiple episodes (eg, a cardiac event associated with diabetes and CHF); we included the total amount of such claims to be as inclusive as possible. Thus, our outcomes focus on medical costs pertaining to the management and treatment of diabetes and diabetes-related events. [37] [38] [39] We constructed 3 outcomes: (1) total cost of diabetesrelated care, (2) outpatient medical costs of diabetes-related care, and (3) inpatient costs of diabetes-related care. A patient's total cost of diabetes-related care was all diabetesrelated costs identified by the ESE software including imputed pharmacy costs, if needed. Outpatient costs of diabetes-related care are claims from outpatient primary and specialty care services (clinic visits, scheduled procedures, outpatient labs, and outpatient prescriptions). In the context of a diabetes episode, they are resources typically used to manage a patient toward desired outcomes such as evidenced-based clinical goals. Inpatient costs of diabetes-related care were costs from hospital-based or emergency care (emergency transport charges, emergency department fees, imaging or lab charges, surgical fees, inpatient services and facility fees, and inpatient pharmacy). We hypothesized that higher functioning PCMH clinical systems would reduce this type of medical care.
Our cost outcomes are based on a standardized measure of utilization, the HealthPartners Relative Resource Value (HPRRV). HPRRVs are based on Centers for Medicare and Medicaid Services' (CMS) relative value units, inpatient diagnosis-related group (DRG), and Ambulatory Payment Classifications weights. They include inpatient care, outpatient surgery, emergency room services, and pharmacy services. The logic is to apply a standardized fee schedule across all providers by developing standardized costs for each CPT procedure, hospital DRG, and pharmacy code that is dependent on the type of procedure/service/prescription provided, but independent of the place of service, type of insurance coverage, or year. This fee schedule was developed by constructing a weighted average of billed amounts across all contracted providers for each CPT procedure code, hospital DRG, and National Drug Code.
Covariates
Diabetes patients are managed to clinical goals. National Committee for Quality Assurance standards and MNCM define quality diabetes care as a patient meeting the following goals: glycated hemoglobin (A1C) < 8%, systolic blood pressure < 130 mm Hg, and low-density lipoprotein (LDL) measure < 100 mg/dL. Patients currently not at goal are treated toward that goal, and current clinical condition can significantly impact costs through increased visits, increased testing, and frequent modification of pharmaceutical scripts. However, physicians must balance the intensity of diabetes care according to patient age and other comorbidities. Because the direction of the relationship between attainment of clinical goals and costs is unclear, we examined 2 specifications. The first adjusted for all these competing factors by considering patient demographics (age, sex), comorbidities (CHF, COPD, HTN, CVD), clinical status [A1C at goal, LDL at goal, blood pressure (BP) at goal], and treatment variation (medication fills) as covariates. The second excluded clinical status and adjusted for only patient demographics (age, sex), comorbidities (CHF, COPD, HTN, CVD), and treatment variation (medication fills). Here, we present results from the first specification. Results from the second are provided as an online supplemental table, Supplementary Digital Content http://links.lww.com/MLR/A298, and differences between the 2 are discussed in the results section.
Analytic Approach
First, we tested for significant variation (ie, clustering) at the medical group level using a likelihood ratio test set at the 5% level. This analysis indicated that no significant proportion of the overall variation was attributed to the medical group (ICCE0). Second, we constructed a baseline patient-level model for each outcome. Covariates significant at the 10% level in univariate models were candidates for the multivariate model. Candidate covariates were screened for correlation and multicolinearity before the development of the final multivariate model and after making appropriate adjustments. Covariates and interactions significant at the 10% and 5% levels were retained, respectively. Third, PPC-RS system scores were analyzed. Each domain score (HCO, Delivery System Redesign, Clinical Information System, Decision Support, and Self-Management Support) and the overall PPC-RS score were considered in a separate, multivariate regression model that adjusted for covariates identified as significant in prior steps. Cross-level interactions with patientlevel factors significant at the 5% level were retained. Finally, a model incorporating all of the domain scores was fit.
A generalized linear model with gamma-distributed errors was found preferable to a log-transformed model. [40] [41] To protect against heteroskedasticity, a robust covariance estimator was used.
Because only 781 (39%) of the included patients had potentially avoidable resource use, a 2-part model was used when modeling this outcome. 42 The first part estimated the likelihood of any utilization using a multivariate, logistic regression. The second part modeled avoidable resource use among those with utilization. Our final cost estimates were derived by conditioning estimated cost effects upon estimated likelihood of any utilization. Table 2 provides information on the demographics, clinical characteristics, and utilization of our analytic sample. Subjects averaged 54 years, 42% were female, and the mean body mass index was 34.4 kg/m 2 (SD 7.6). Most had at least 1 comorbid condition with HTN (54%) being the most prevalent.
RESULTS
Diabetes-related costs, including pharmaceutical use, varied widely. Mean total costs of diabetes-related care were $4137, and were heavily skewed with a range from $305 to $73,029. Most patients (61%) had no inpatient costs of diabetes-related care, and there was variation among those who did (range = $47.07 to $63,752.54).
The 27 medical groups varied in terms of their patient demographics and clinical practice system scores ( Table 3 ). The mean number of patients per medical group was 63 (range = 8-179). The medical group median total costs of diabetes-related care per patient averaged $3243 (range $2091-$4768). Median per patient outpatient costs of diabetes-related care were less variable (mean $2641, SD = $531). The level of clinical practice system implementation varied considerably. Overall PPC-RS system scores ranged from 32.2 to 95.8 with an average of 67.9.
The following factors were found to be significant in all 3 baseline patient-level models: age, sex, smoking status, CHF, COPD, CVD, aspirin use, A1C at goal, LDL at goal, BP at goal, and outpatient pharmaceutical use. Women incurred more outpatient but fewer inpatient diabetes-related costs than men. All 3 outcomes increased with age and pharmaceutical use, but relationships were nonlinear and squared terms were used. All diabetes-quality goals (A1C, LDL, and BP) were associated with lower diabetes-related costs. The only cross-level interaction retained was with CHF and total PPC-RS scores in the inpatient diabetesrelated cost model. Table 4 shows the estimated relations between clinical practice systems and costs from the specification including diabetes-quality goals as covariates. Results are presented as the estimated average per-person cost impact due to a 10% increase in the PCMH-related clinical system score above the sample average of 67.9. Although overall PPC-RS scores are associated with a decrease in the total, outpatient, and inpatient diabetes-related costs, none of these associations was significant.
The HCO domain score is significantly related to total diabetes-related costs (P = 0.04), and this appears to be driven by a negative correlation with inpatient diabetes-related costs. For the specification including diabetes-quality goals, a 10% increase in an HCO score was associated with both a decreased likelihood [odds ratio (OR) = 0.97, P = 0.04] and a decreased amount (P = 0.04) of inpatient diabetesrelated costs, resulting in an estimated overall average perperson decrease of $25.20. When diabetes-quality goals were excluded, the association with decreased likelihood remained significant (OR = 0.97; P = 0.04), but the relationship with inpatient costs was not (P = 0.406), resulting in a significant average per-person decrease of $33.37 (95% confidence interval, À $48.23 to À $13.89).
A clearer understanding of this association comes from examining individual elements of the PPC-RS ( Table 1 ). The HCO domain is composed of 3 questions: Formal Quality Improvement Activities (QI), Performance Measurement (PM), and Individual Feedback (IF). Only 1 medical group failed to engage in any of these activities, whereas 3 engaged in only formal QI activities. One engaged in both QI and PM and the remaining 22 medical groups engaged in all three. After adjusting for covariates, patients at the medical group with no QI activities averaged $125 more in total diabetesrelated costs per patient than those at the 3 medical groups with only formal QI activities. Patients at medical groups with both QI and PM averaged $126 fewer total diabetes-related costs than those at medical groups with only formal QI activities, and patients at the medical groups with all 3 HCO activities (QI, PM, and IF) averaged $245 fewer total diabetesrelated costs than patients at medical groups with only QI.
A similar relationship was observed with Decision Support. For the specification including diabetes-quality goals, patients who received care at medical groups with higher levels of decision support had a significantly lower likelihood of incurring any inpatient diabetes-related costs (OR = 0.94, P = 0.02) with no change in the average amount of inpatient diabetes-related costs (P = 0.86). This resulted in a net average marginal reduction of $26 for every 10% increase in a medical group's decision support score above the sample average of 56.7. Similarly, when diabetes-quality goals were excluded, there was a lower likelihood of incurring any inpatient diabetes-related costs (OR = 0.943, P = 0.02) with no change in the average inpatient diabetes-related costs (P = 0.79).
Again, individual components provide a clearer illustration. Nine components comprise the Decision Support domain score ( Table 1 ). All 27 medical groups have implemented age-appropriate preventive services and all but 1 has implemented evidence-based diabetes standards. The groups differ in the implementation of clinical reminders, alerts, and abnormal test protocols. After adjusting for the covariates, only clinical reminders for counseling had a 
DISCUSSION
This cross-sectional study suggests that selected domains of the PCMH are associated with lower diabetes-related health care costs. Patients were less likely to have potentially avoidable inpatient costs of diabetes-related care such as emergency care and unscheduled hospital stays and had lower total costs of diabetes-related care when they received care from medical groups that had implemented PCMH-related systems such as formal quality improvement initiatives, individualized performance feedback, and clinician reminders.
We did not find a significant cost relationship between the implementation of systems and outpatient diabetes-related costs ( Table 4 ). This is not surprising because implementation of systems in domains such as Delivery System Redesign, Clinical Information Systems, and Decision Support may actually increase the utilization of some services such as medication use (ie, improved adherence and/or persistence) and care management. Although higher delivery system redesign scores were significantly associated with increased outpatient diabetes-related costs (P = 0.01), the estimated monetary impact was small ($.38/patient/y).
Prior studies have attempted to correlate PCMH domains with medical costs and quality. Using a related measurement of clinical systems, Gillies et al, 43 and Solberg et al 25, 44 have shown a relationship with quality. Flottemesch et al 23 showed a correlation between PCMH systems and reduced costs among complex patients, and Fontaine et al 45 indicated that a consistent source of primary care appears to be related to lower utilization. This study is different because of the focus on a particular chronic disease. A study by Scholle et al 46 indicates a negative relationship between the quality of care using Healthcare Effectiveness Data and Information Set quality measures in diabetes and resource use measures of total utilization of inpatient, surgical, and procedures by the same patients at the health plan level.
The cross-sectional design precludes causal inference and prevents analysis of the potential impact of PCMH over time even though attempts to control for differences in The denominator is the total number of episodes for medical group. complexity and care patterns were made. A longitudinal design incorporating patient changes (prior year utilization, duration with diabetes, etc.) and system changes would better assess the impact of PCMH-related clinical systems. Other limitations include the relatively small sample of medical groups from a single geographic region, and the observation that baseline levels of diabetes care were somewhat better in these medical groups compared with national data. Finally, because of data limitations, we were unable to examine particular subgroups of patients (eg, those with a particular comorbidity or highly complex patients).
The study relied on medical directors' self-reports of the presence of PCMH domains. Previous studies indicate that medical directors are more likely to underreport systems in this community than to overreport them, at least when there was no financial incentive for the latter. 26 The PPC identifies the existence of clinical systems, and focuses on the clinical system structure. It does not capture other PCMH-related elements. [47] [48] However, these limitations have the likely impact of understating the potential impact of the PCMH and make our findings even more interesting.
Finally, there are many factors that can confound chronic disease care. We attempted to control for these by incorporating a variety of covariates. Table 4 reports results from a specification adjusting for age, sex, certain comorbidities, pharmaceutical drug use, and diabetes-related outcomes (HbA1C, blood pressure, and LDL). Nonetheless, this set of variables was far from exhaustive, and we were unable to account for the impact of factors such as race, socioeconomic status, and certain comorbidities such as episodic depression. [49] [50] Further, some may question the inclusion of diabetes-related outcomes in our final models. Improved clinical systems are likely to improve these outcomes and thereby lead to reduced costs over time. However, they are also likely to lead to increased costs in the short term as patients are treated to goal. We felt adjusting for these factors would lead to better estimates of the relationship between systems and costs, and report results from this specification in our tables. However, differences from an alternative specification excluding these factors are noted in the text. The study's findings regarding the association between PCMH clinical practice systems and costs directly attributable to diabetes care should not be generalized to all costs without further examination. Most adults with diabetes have other chronic conditions that add substantially to their health care costs, and systems focused on improving diabetes care may or may not assist in managing the increased complexity brought by these conditions. 24 Additional research exploring whether improved clinical systems for 1 chronic disease assist in managing complex cases and further reduce total costs is needed.
Despite these limitations, the results of this study are interesting and important. The data suggest that some PCMH On the basis of a 10% increase in the system score above the sample average among those incurring costs. z On the basis of a 10% increase in the system score and accounting for changes in both the likelihood of inpatient utilization and the amount of inpatient utilization. CHF indicates congestive heart failure; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; HTN, hypertension; LDL, low-density lipoprotein; OR, odds ratio; PPC-RS, Physician Practice Connections Readiness Survey. domains may be related to lower costs because of hospitalizations and emergency care. However, no PCMH domain was related to lower outpatient costs and some PCMH domains significantly increased costs, although by small amounts of money.
The data are consistent with the hypothesis that the existence of certain clinical systems associated with the PCMH may lead to reduced hospital and emergency care use. However, the relationships between systems, quality, and cost are complex. At best, the current study provides both direction and justification for more extensive and prospective evaluations of these interrelationships. For example, planned CMS medical home demonstrations should consider competing cost patterns and relationships in their design and evaluation.
CONCLUSIONS
Although overall PCMH domain scores were not related to lower diabetes-related health care costs, selected PCMH domains were associated with lower total diabetesrelated costs or lower inpatient diabetes-related costs. However, these associations were relatively small compared with the average patient diabetes-related costs. Efforts to promote and evaluate the PCMH should include a controlled longitudinal evaluation of how such models of care are related to outpatient costs for managing chronic and preventive care and their impact on costs for unexpected care such as unplanned hospitalizations and emergency visits.
